At 68 weeks, the semaglutide group averaged 14.9 percent weight loss from baseline, but the six-month data point shows approximately 13.8 percent, meaning most of the total weight loss has already occurred by this stage
Instead, focus on sipping water throughout the day between meals
This step, combined with BMI criteria and a documented lifestyle modification program, reflects Kaiser NW's conservative formulary approach
Clinical data from the STEP 1 trial shows average weight loss of approximately 5.9 percent of baseline body weight at 12 weeks
2025 comprehensive formulary, Kaiser Permanente 2025 Medicare Part D comprehensive formulary, Kaiser Permanente Criteria-based consultation prescribing program (injectable semaglutide), Kaiser Permanente Northwest Region Novo Nordisk receives FDA approval of Ozempic (semaglutide) injection for the treatment of adults with Type 2 diabetes, PR Newswire (2017) Understanding drug tiers, Patient Advocate Foundation Drug formulary (covered drugs), Kaiser Permanente Find out if your insurance covers Ozempic, NovoCare Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
